Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice

被引:51
作者
Barrick, Cordelia J. [2 ,5 ]
Roberts, Reade B. [2 ]
Rojas, Mauricio [3 ,6 ]
Rajamannan, Nalini M. [9 ]
Suitt, Carolyn B. [4 ]
O'Brien, Kevin D. [10 ]
Smyth, Susan S. [11 ]
Threadgill, David W. [1 ,2 ,5 ,6 ,7 ,8 ]
机构
[1] N Carolina State Univ, Dept Genet, Raleigh, NC 27695 USA
[2] Univ N Carolina, Dept Genet, Chapel Hill, NC USA
[3] Univ N Carolina, Dept Med, Chapel Hill, NC USA
[4] Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC USA
[5] Univ N Carolina, Dept Curriculum Toxicol, Chapel Hill, NC USA
[6] Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC USA
[7] Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC USA
[8] Univ N Carolina, Ctr Environm Hlth & Susceptibil, Chapel Hill, NC USA
[9] Northwestern Univ, Dept Med, Chicago, IL 60611 USA
[10] Univ Washington, Dept Med, Seattle, WA USA
[11] Univ Kentucky, Cardiovasc Res Ctr, Lexington, KY USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 2009年 / 297卷 / 01期
基金
美国国家卫生研究院;
关键词
epidermal growth factor receptor aortic sclerosis; hypertrophy; aortic stenosis; valvulogenesis; GROWTH-FACTOR RECEPTOR; VALVE DISEASE; TARGETED DISRUPTION; EARLY LESION; HEART; MUTANT; AGE; DYSFUNCTION; PROGRESSION; ASSOCIATION;
D O I
10.1152/ajpheart.00866.2008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Barrick CJ, Roberts RB, Rojas M, Rajamannan NM, Suitt CB, O'Brien KD, Smyth SS, Threadgill DW. Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice. Am J Physiol Heart Circ Physiol 297: H65-H75, 2009. First published May 15, 2009; doi:10.1152/ajpheart.00866.2008.-Epidermal growth factor receptor (EGFR) signaling contributes to aortic valve development in mice. Because developmental phenotypes in Egfr-null mice are dependent on genetic background, the hypomorphic Egfr(wa2) allele was made congenic on C57BL/6J (B6) and 129S1/SvImJ (129) backgrounds and used to identify the underlying cellular cause of EGFR-related aortic valve abnormalities. Egfr(wa2/wa2) mice on both genetic backgrounds develop aortic valve hyperplasia. Many B6-Egfr(wa2/wa2) mice die before weaning, and those surviving to 3 mo of age or older develop severe left ventricular hypertrophy and heart failure. The cardiac phenotype was accompanied by significantly thicker aortic cusps and larger transvalvular gradients in B6-Egfr(wa2/wa2) mice compared with heterozygous controls and age-matched Egfr(wa2) homozygous mice on either 129 or B6129F1 backgrounds. Histological analysis revealed cellular changes in B6-Egfr(wa2/wa2) aortic valves underlying elevated pressure gradients and progression to heart failure, including increased cellular proliferation, ectopic cartilage formation, extensive calcification, and inflammatory infiltrate, mimicking changes seen in human calcific aortic stenosis. Despite having congenitally enlarged valves, 129 and B6129F1-Egfr(wa2/wa2) mice have normal lifespans, absence of left ventricular hypertrophy, and normal systolic function. These results show the requirement of EGFR activity for normal valvulogenesis and demonstrate that dominantly acting genetic modifiers curtail pathological changes in congenitally deformed valves. These studies provide a novel model of aortic sclerosis and stenosis and suggest that long-term inhibition of EGFR signaling for cancer therapy may have unexpected consequences on aortic valves in susceptible individuals.
引用
收藏
页码:H65 / H75
页数:11
相关论文
共 60 条
  • [1] Alipour Massoud S, 2003, Am J Geriatr Cardiol, V12, P201, DOI 10.1111/j.1076-7460.2003.02067.x
  • [2] Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice
    Barrick, Cordelia J.
    Yu, Ming
    Chao, Hann-Hsiang
    Threadgill, David W.
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2008, 228 (03) : 315 - 325
  • [3] Cardiac response to pressure overload in 129S1/SvImJ and C57BL/6J mice: temporal- and background-dependent development of concentric left ventricular hypertrophy
    Barrick, Cordelia J.
    Rojas, Mauricio
    Schoonhoven, Robert
    Smyth, Susan S.
    Threadgill, David W.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2007, 292 (05): : H2119 - H2130
  • [4] Guidelines for the management of patients with valvular heart disease - Executive summary - A report of the American College of Cardiology American Heart Association task force on practice guidelines (committee on management of patients with valvular heart disease)
    Bonow, RO
    Carabello, B
    de Leon, AC
    Edmunds, LH
    Fedderly, BJ
    Freed, MD
    Gaasch, WH
    McKay, CR
    Nishimura, RA
    O'Gara, PT
    O'Rourke, RA
    Rahimtoola, SH
    Ritchie, JL
    Cheitlin, MD
    Eagle, KA
    Gardner, TJ
    Garson, A
    Gibbons, RJ
    Russell, RO
    Ryan, TJ
    Smith, SC
    [J]. CIRCULATION, 1998, 98 (18) : 1949 - 1984
  • [5] ACC/AHA 2006 guidelines for the management of patients with valvular heart disease
    Bonow, Robert O.
    Carabello, Blase A.
    Chatterjee, Kanu
    de Leon, Antonio C., Jr.
    Faxon, David P.
    Freed, Michael D.
    Gaasch, William H.
    Lytle, Bruce Whitney
    Nishimura, Rick A.
    O'Gara, Patrick T.
    O'Rourke, Robert A.
    Otto, Catherine M.
    Shah, Pravin M.
    Shanewise, Jack S.
    Smith, Sidney C., Jr.
    Jacobs, Alice K.
    Adams, Cynthia D.
    Anderson, Jeffrey L.
    Antman, Elliott M.
    Faxon, David P.
    Fuster, Valentin
    Halperin, Jonathan L.
    Hiratzka, Loren F.
    Hunt, Sharon A.
    Lytle, Bruce W.
    Nishimura, Rick
    Page, Richard L.
    Riegel, Barbara
    [J]. CIRCULATION, 2006, 114 (05) : E84 - E231
  • [6] BRAUNWALD E, 1998, VALVULAR HEART DIS
  • [7] Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
    Burris, HA
    Hurwitz, HI
    Dees, EC
    Dowlati, A
    Blackwell, KL
    O'Neil, B
    Marcom, PK
    Ellis, MJ
    Overmoyer, B
    Jones, SF
    Harris, JL
    Smith, DA
    Koch, KM
    Stead, A
    Mangum, S
    Spector, NL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5305 - 5313
  • [8] Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation
    Caira, FC
    Stock, SR
    Gleason, TG
    McGee, EC
    Huang, J
    Bonow, RO
    Spelsberg, TC
    McCarthy, PM
    Rahimtoola, SH
    Rajamannan, NM
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (08) : 1707 - 1712
  • [9] CARLSON FL, 1990, HISTOTECHNOLOGY SELF
  • [10] Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis
    Chen, BB
    Bronson, RT
    Klaman, LD
    Hampton, TG
    Wang, JF
    Green, PJ
    Magnuson, T
    Douglas, PS
    Morgan, JP
    Neel, BG
    [J]. NATURE GENETICS, 2000, 24 (03) : 296 - 299